Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DRD2 | P14416 | 4/20 | 0.41 |
| ▸ | IDO1 | P14902 | 2/20 | 0.40 |
| ▸ | HTR1A | P08908 | 2/20 | 0.36 |
| ▸ | HTR2A | P28223 | 2/20 | 0.36 |
| ▸ | HTR7 | P34969 | 2/20 | 0.36 |
| ▸ | HTR6 | P50406 | 2/20 | 0.36 |
| ▸ | HSD11B1 | P28845 | 2/20 | 0.35 |
| ▸ | EPAS1 | Q99814 | 1/20 | 0.35 |
| ▸ | AR | P10275 | 1/20 | 0.35 |
| ▸ | NR3C2 | P08235 | 3/20 | 0.35 |
| ▸ | PPARG | P37231 | 1/20 | 0.34 |
| ▸ | RBP4 | P02753 | 1/20 | 0.33 |
| ▸ | TTR | P02766 | 1/20 | 0.33 |
| ▸ | NR3C1 | P04150 | 4/20 | 0.33 |
| ▸ | P2RY1 | P47900 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL26020414 | 0.86 | IDO1 (0.44) | DRD2IDO1HSD11B1ARNR3C2 | |
| SCHEMBL13347574 | 0.80 | HTR2A (0.45) | DRD2IDO1HTR2AARNR3C2 | |
| SCHEMBL13020168 | 0.79 | HSD11B1 (0.42) | IDO1HTR1AHSD11B1PPARG | |
| SCHEMBL13008512 | 0.78 | HSPB1 (0.42) | EPAS1AR | |
| SCHEMBL6764191 | 0.78 | CA3 (0.38) | HTR2A | |
| SCHEMBL6764247 | 0.76 | FFAR1 (0.39) | HTR2A | |
| SCHEMBL24176727 | 0.76 | DRD2 (0.45) | DRD2IDO1HTR1AHTR2AHTR7 | |
| SCHEMBL21974055 | 0.74 | KCNH2 (0.30) | NR3C2NR3C1 | |
| SCHEMBL14237535 | 0.74 | IDO1 (0.41) | DRD2IDO1HTR1AHTR2AHTR7 | |
| SCHEMBL18356035 | 0.74 | NFE2L2 (0.46) | NR3C2NR3C1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230257382-A1 | HETEROCYCLIC COMPOUND AND USE THEREOF | WUHAN LL SCIENCE AND TECHNOLOGY DEVELOPMENT CO., LTD. (CN) | 2023-08-17 | — | — | US | disclosed |
| US-20230257382-A1 | HETEROCYCLIC COMPOUND AND USE THEREOF | WUHAN LL SCIENCE AND TECHNOLOGY DEVELOPMENT CO., LTD. (CN) | 2023-08-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230257382-A1 | HETEROCYCLIC COMPOUND AND USE THEREOF | TRPC5, TRPC1, GOT1 | DRD2 3043/4885IDO1 184/4885HTR1A 554/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.